首页> 外文期刊>The American Surgeon >The Impact of Multidisciplinary Therapy in Node-Positive Rectal Cancer
【24h】

The Impact of Multidisciplinary Therapy in Node-Positive Rectal Cancer

机译:多学科治疗对淋巴结阳性直肠癌的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Multidisciplinary therapy (MDT) of node-positive rectal cancer is considered optimal. We performed a retrospective cohort study of node positive rectal cancer patients diagnosed between January 1, 1994 and December 31, 2003 in Region 5 of the California Cancer Registry to determine the impact of MDT on disease specific survival (DSS). During the study period, 398 patients with stage III rectal cancer were identified. Only 251 patients (63.1%) received radiation (XRT). Patients receiving XRT had significantly improved survival when compared with those who did not (5 year DSS 55% with XRT vs 36% without XRT, median follow-up 43 months, P < 0.001). There was no statistically significant difference in T stage (P = 0.41), the number of N1 patients (P = 0.45), or the number of positive nodes harvested (mean 11.5 w/o XRT vs 12.8 w/XRT, P = 0.37) between patients receiving XRT and those who did not. Patients receiving XRT were far more likely to receive systemic chemotherapy (83% vs 27%, P < 0.0001). Multidisciplinary therapy of node-positive rectal cancer is associated with improved DSS. However, substantial numbers of node positive rectal cancer patients are not receiving MDT. Greater efforts are needed to implement consistent multidisciplinary algorithms into rectal cancer management. [PUBLICATION ABSTRACT]
机译:淋巴结阳性直肠癌的多学科治疗(MDT)被认为是最佳的。我们对1994年1月1日至2003年12月31日之间在加利福尼亚州癌症登记处诊断为淋巴结阳性的直肠癌患者进行了一项回顾性队列研究,以确定MDT对疾病特异性存活率(DSS)的影响。在研究期间,确定了398例III期直肠癌患者。仅251名患者(63.1%)接受了放射(XRT)。与未接受XRT的患者相比,接受XRT的患者的生存率有了显着提高(5年DSS接受XRT的患者为55%,未接受XRT的患者为36%,中位随访43个月,P <0.001)。在T期(P = 0.41),N1病人(P = 0.45)或收获的阳性淋巴结数目(XRT分别为11.5 w / o XRT与12.8 w / XRT之间,P = 0.37)差异无统计学意义。在接受XRT的患者与未接受XRT的患者之间。接受XRT的患者接受全身化疗的可能性要高得多(83%比27%,P <0.0001)。淋巴结阳性直肠癌的多学科治疗与改善DSS有关。但是,许多淋巴结阳性的直肠癌患者未接受MDT。需要付出更大的努力才能在直肠癌治疗中实施一致的多学科算法。 [出版物摘要]

著录项

  • 来源
    《The American Surgeon》 |2010年第10期|p.1163-1166|共4页
  • 作者单位

    MATTHEW ROOS, M.D.,* JAN H. WONG, M.D.,*[double dagger] SHARMILA ROY-CHOWDHURY, M.D.,* SHARON S. LUM, M.D.,*JOHN W. MORGAN, DR.P.H.,[dagger][double dagger] KEVORK KAZANJIAN, M.D.*From the *Division of Surgical Oncology and [dagger] School of Public Health, Loma Linda University Schoolof Medicine, Loma Linda, California and Region 5 of the California Cancer Registry, Desert SierraCancer Surveillance Program, Loma Linda University Medical Center, Loma Linda, CaliforniaSupported in part by NCI SEER contracts N02-PC-15105 and CDC NPCR contract U58DP000807-01.Presented at the 21st Annual Scientific Meeting of the Southern California Chapter of the American College of Surgeons in Santa Barbara, CA, January 22-24, 2010.Address correspondence and reprint requests to Kevork Kazanjian, M.D., Loma Linda University School of Medicine, Department of Surgery, Division of Surgical Oncology, 1 1 175 Campus Street, CP 21 1 1 1, Loma Linda, CA 92350. E-mail: kkazanjian@llu.edu.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号